How Long Do You Take Allergy Shots? Finite Treatment vs Lifelong Medications

Allergy shots do not 'cure' allergies in the absolute sense, but they can induce clinical remission in many patients — a state where symptoms are absent or minimal even without daily medication. Durham et al. in NEJM 1999 demonstrated that 3 to 4 years of grass pollen SCIT produced prolonged remission lasting at least 3 years post-treatment. Eng et al. in Allergy 2006 documented continued benefit at 12 years. The immune changes — including IgG4 blocking antibodies, regulatory T-cell expansion, and mast cell desensitization — can be long-lasting. However, 10 to 25 percent of patients experience symptom relapse within 3 years of stopping, and underlying sensitization can persist even when clinical remission is maintained. The correct framing is disease modification, not cure.

Clinical trials and meta-analyses consistently show 50 to 80 percent of SCIT-treated patients reduce or eliminate their daily allergy medications. The Calderon Cochrane review of 51 randomized controlled trials found a medication score standardized mean difference of -0.57, meaning treated patients used significantly less rescue medication than placebo controls. In some trials and real-world cohorts, the reduction is more dramatic: Walker et al. in JACI 2001 reported an 80 percent reduction in rescue medication use in grass SCIT patients. Individual results vary based on allergen type, treatment duration, and severity of baseline disease. Your allergist should guide any medication tapering — do not reduce allergy medications without medical supervision.

Post-treatment benefit from allergy shots varies considerably by individual and course length but is typically measured in years. Durham et al. established in NEJM 1999 that 3 to 4 years of grass pollen SCIT produced benefit lasting at least 3 years after stopping. Eng et al.'s 12-year follow-up in Allergy 2006 confirmed that both symptom scores and medication use remained significantly lower in former SCIT patients versus controls more than a decade post-treatment — though skin test reactivity had partially returned by year 12, suggesting immunological waning without clinical relapse. Five-year courses appear to produce longer-lasting post-treatment benefit than 3-year courses. The Penagos and Durham consensus review in JACI 2022 cited a 7-to-12-year benefit window for well-completed courses.

For patients with confirmed IgE-mediated allergic rhinitis, a 3-to-5-year SCIT course compares favorably to decades of daily medication on several dimensions: SCIT is the only disease-modifying treatment (pharmacotherapy offers no disease modification regardless of duration), post-treatment benefit persists years after stopping (antihistamines stop working within hours of missing a dose), and SCIT may prevent new allergen sensitizations and reduce asthma risk in children. Financially, Hankin et al.'s Medicaid analysis in Annals of Allergy 2010 found 33 percent lower total healthcare costs in SCIT-treated patients versus matched controls. The break-even period is typically 5 to 8 years after starting treatment. However, only confirmed IgE-mediated allergic disease responds to immunotherapy — this is why specific IgE testing is an essential prerequisite.

Taking allergy shots for only 1 to 2 years — less than the AAAAI-recommended minimum of 3 years of maintenance — significantly increases the risk of symptom relapse after stopping. The EAACI guidelines explicitly state that 2-year courses are insufficient for sustained post-treatment benefit, citing evidence that the immune changes required for durable remission require at least 3 years of treatment. Nouri-Aria et al. in JACI 2004 documented higher relapse rates in patients who stopped before completing 3 years. Clinical improvement noticed during a short course may represent temporary desensitization rather than the deeper immune reprogramming — including regulatory T-cell expansion and IgG4 class-switching — that sustains long-term benefit. Completing the full recommended course is the strongest predictor of durable outcomes.

Evidence from several studies suggests that SCIT may prevent patients from developing new allergic sensitizations over time, though this finding is stronger in observational data than in randomized trials. Des Roches et al. in JACI 1997 found that 45 percent of SCIT-treated mite-monosensitized children developed no new sensitizations versus 0 percent of controls. Purello-D'Ambrosio in Clinical and Experimental Allergy 2001 found new sensitizations in only 23.75 percent of SCIT-treated patients versus 68 percent of untreated patients over 4 years. Daily antihistamines and nasal steroids have no documented effect on preventing new sensitizations. Di Bona's 2017 systematic review in Allergy concluded that while positive observational findings are consistent, the randomized trial evidence remains limited and inconclusive due to study design limitations.

For most allergic conditions including rhinitis, conjunctivitis, and asthma, allergy shots are a finite 3-to-5-year course after which treatment ends — even for patients with severe disease. The notable exception is venom immunotherapy for patients with severe anaphylactic reactions to Hymenoptera stings (bees, wasps, hornets). Golden et al. in JACI 2011 established that patients with severe initial systemic reactions, mastocytosis, or elevated baseline tryptase may require indefinite venom immunotherapy because their residual systemic-reaction risk remains 5 to 15 percent even after 5 years. For inhalant allergens (pollen, dust mites, pet dander, mold), the standard recommendation is 3 to 5 years with discontinuation guided by sustained symptom improvement through at least 1 to 2 full allergen seasons.